Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signalingAnnika De Sousa Linhares, Peter Steinberger, Claire Battin et al.|Scientific Reports|2019Cited by 196
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, Christoph Zielinski, C Wiltschke et al.|Breast Cancer Research and Treatment|2009Cited by 120
Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedulesAngelika Wagner, Ursula Wiedermann, Michael Kundi et al.|Scientific Reports|2018Cited by 113
Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10Erika Garner‐Spitzer, Ursula Wiedermann, Angelika Wagner et al.|The Journal of Immunology|2013Cited by 78
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel DiseaseAngelika Wagner, Ursula Wiedermann, Erika Garner‐Spitzer et al.|Frontiers in Immunology|2022Cited by 64